Agents Used in Antiretroviral Therapy
Summary
- Rilpivirine therapy failure is associated with mutations at L100I, K101E/P, E138A/G/K/Q/R, V179L, Y181C/I/V, Y188L, H221Y, F227C, and M230I/L[Wensing 2017]
- Resistance to rilpivirine in phase III clinical trials led to cross-resistance to etravirine in 90% of cases[Cohen 2011; Molina 2011]
- Rilpivirine is indicated in combination with other antiretroviral agents for treatment of HIV infection in treatment-naive adult patients with HIV-1 RNA ≤ 100,000 copies/mL in United States[FDA Rilpivirine]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content